牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-19-022677 Act: 34 Size: 30 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-11-06 AccNo: 0001213900-19-022222 Size: 1 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-11-04 AccNo: 0001213900-19-021893 Size: 31 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-10-31 AccNo: 0001213900-19-021570 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-10-24 AccNo: 0001178913-19-002508 Size: 42 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT - Notice of Effectiveness Filed: 2019-10-18 AccNo: 9999999995-19-002340 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2019-10-18 AccNo: 0001213900-19-020597 Size: 597 KB 网页链接
$灿菲特生物制药(CANF)$ 424B3 - Prospectus [Rule 424(b)(3)] Filed: 2019-10-18 AccNo: 0001213900-19-020619 Size: 471 KB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2019-10-17 AccNo: 0001213900-19-020567 Size: 813 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-10-17 AccNo: 0001178913-19-002484 Size: 110 KB 网页链接